logo
Samsung may build Qualcomm's most advanced chip ever for the Galaxy S26 series

Samsung may build Qualcomm's most advanced chip ever for the Galaxy S26 series

C. Scott Brown / Android Authority
TL;DR Samsung could reportedly fabricate one variant of the Snapdragon 8 Elite 2 for Qualcomm.
While the normal chip would be made with a 3nm TSMC process, Samsung's could be a 2nm chip.
This 2nm Snapdragon 8 Elite 2 may debut with the Galaxy S26.
There's arguably no single component that more influences how a smartphone comes together than the choice of its system-on-a-chip (SoC). And while a phone is a whole lot more than just how fast it can crunch numbers, the decision around which SoC to use influences everything from the screens and cameras a handset can support, to how power-efficient the phone will be. Right now, Qualcomm's Snapdragon chips dominate popular Android hardware, with the Snapdragon 8 Elite powering many of this year's best phones. But if this latest report we're hearing turns out to be accurate, the upcoming Snapdragon 8 Elite 2 could shake up the SoC industry in some surprising ways.
Qualcomm designs its Snapdragon chips, but when it comes to actually manufacturing them, it has historically relied upon fabrication partners like TSMC and Samsung. But in recent years, its highest-end flagship chips have exclusively been produced by TSMC. That's included the Snapdragon 8 Elite, built on TSMC's 3nm process.
We've recently been talking about the next step forward, and when we might expect to see 2nm chips start to become commercially viable. That's included a rumor that Google could get an early start with a 2nm Tensor G6 chip for the Pixel 11, made by TSMC. While at the time we hadn't heard of earlier plans for a competing 2nm chip, that's now changing.
Robert Triggs / Android Authority
According to South Korea's Business Post, Qualcomm could be planning something a little strange for the Snapdragon 8 Elite 2. Much like we saw with the S25 series and its special Snapdragon 8 Elite for Galaxy chips, Samsung could again be getting a special edition of Qualcomm's next chip with a few exclusive upgrades. But this time around, Qualcomm could actually tap Samsung to fabricate the chip itself.
The reason why that move would be particularly interesting is because Samsung has its own promising 2nm process, and industry sources expect that this version of the Snapdragon 8 Elite 2 (referred to internally as 'Kaanapali S') could be manufactured using it. And if those indeed end up in the Galaxy S26 family, it could be Samsung, rather than Google, that first puts these kind of next-gen chips in your hand.
Yields have reported already risen from 30% to 40% for Samsung's 2nm process, and while that's still a bit below where companies target for profitability, if that number keeps moving in the right direction, Samsung could be in good shape in just a few more months. The company's also been looking at 1.4nm chips, but has supposedly delayed those plans in order to further refine its 2nm workflow.
Ultimately, which company is first with a phone running a 2nm chip won't come down to more than bragging rights, and regardless of who wins, everyone else is going to catch up in short order. But that doesn't make us any less excited to think about the tiny atomic-scale places these processors are going.
Got a tip? Talk to us! Email our staff at
Email our staff at news@androidauthority.com . You can stay anonymous or get credit for the info, it's your choice.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gold Steadies as Traders Mull Mideast Truce, Fed's Rate-Cut Path
Gold Steadies as Traders Mull Mideast Truce, Fed's Rate-Cut Path

Bloomberg

time11 minutes ago

  • Bloomberg

Gold Steadies as Traders Mull Mideast Truce, Fed's Rate-Cut Path

Gold steadied as investors watched for clearer signs that Israel-Iran tensions won't spill over into war again, and for fresh signals regarding the Federal Reserve's rate-cut plans. Bullion traded near $3,335 an ounce early in Asia after closing slightly higher on Wednesday. President Donald Trump said that US and Iranian officials will meet next week and Israel's conflict with Tehran was effectively over, but still warned fighting 'could maybe start soon.'

This amazing Samsung gaming monitor is $300 off and comes with a free headset!
This amazing Samsung gaming monitor is $300 off and comes with a free headset!

Android Authority

time22 minutes ago

  • Android Authority

This amazing Samsung gaming monitor is $300 off and comes with a free headset!

Samsung makes some of the best gaming monitors around, especially if you're looking for one of those fancy, huge, curved, ultrawide ones. The Samsung Odyssey OLED G9 (G91SD) 49-Inch Curved Gaming Monitor is an excellent option if you want something less expensive, and today's deal makes it much more enticing. It is $300 off, and you also get a free headset! Get the Samsung Odyssey OLED G9 (G91SD) with a free JBL Quantum ONE headset for $999.99 ($599.95 off) This offer is available directly from Samsung's official website. We're not sure how long the deal will stand. I still want one of those giant curved monitors from Samsung, but they are usually prohibitively expensive. Some great deals come from time to time, though, and here's a really nice one. The Samsung Odyssey OLED G9 (G91SD) 49-Inch Curved Gaming Monitor is usually $1,299.99, but today Sammy is offering some really nice incentives to sign up for it. For starters, it has a $300 discount. On top of that, the brand is throwing in a free JBL Quantum ONE headset valued at $299.95. While not Samsung's best monitor in this category, this is a very capable screen for your gaming sessions. It measures in at 49 inches, so it is pretty huge. Additionally, it comes with a nice Dual QHD resolution of 5,120 x 1,440. This means it is essentially like putting two QHD monitors side by side. It's an OLED panel, so it will also look gorgeous, making colors more vibrant and blacks deeper. You'll get really nice specs, such as a 144Hz refresh rate, a 0.03ms response time, and a 1,800R curvature. Not to mention, the monitor will support plenty of standards gamers love. These include AMD FreeSync Premium Pro, adaptive brightness, VESA DisplayHDR True Black 400, and more. It also comes with plenty of ports, including HDMI, Micro-HDMI, Display Port, and USB-C. If you want to use two devices at once, it can handle both picture-in-picture and picture-by-picture. As for the JBL Quantum ONE headset, our sister, Sound Guys, checked it out, and the team loved its performance. Their main complaint was the higher price point, but in this case, you're getting it for free! Its main highlights include great sound quality, really good sound isolation, a very comfortable design, and an incredible amount of unique features. Check out Sound Guys' full review of the JBL Quantum ONE to learn all about the headset. Sign up for this deal before it goes away! You'll get a fantastic monitor at a good discount, a very good headset for free, and I am even seeing an extra $50 upgrade credit offer. It's hard to beat this deal.

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA
CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA

Yahoo

timean hour ago

  • Yahoo

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA

SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. The NDA submission is mainly based on the results of an open-label, multicenter, randomized controlled confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) conducted in China. The data have been presented in The Lancet and at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, the company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase Ib registrational trial for pancreatic cancer adjuvant treatment and an ongoing investigator-initiated trial for consolidation treatment following adjuvant therapy in patients with resected G/GEJA. Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of the CT041-ST-01 clinical trial, said, "Gastric cancer is a malignancy with a substantial global disease burden and significant treatment challenges. For patients with advanced gastric cancer, in particular, existing therapeutic options and their efficacy remain severely limited, resulting in extremely poor survival outcomes. Within the current treatment landscape for gastric cancer, a growing number of patients have experienced failure with immunotherapy and anti-angiogenic therapies. Treatment choices and potential benefits become even more constrained in the third-line setting and beyond. Consequently, there exists a significant unmet clinical need for advanced gastric cancer patients after second-line treatment failure. The confirmatory randomized controlled clinical trial of satri-cel has clearly demonstrated that, compared with existing standard therapies, satri-cel offers significant advantages and clinical value in extending both progression-free survival (PFS) and overall survival (OS). The trial results have garnered widespread international attention and recognition, providing a solid evidentiary foundation for satri-cel's New Drug Application (NDA) submission. We look forward to the approval and market launch of satri-cel, which will offer a new treatment option for the broader population of gastric cancer patients." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are delighted to announce that the NDA for our self-developed Claudin18.2-targeted CAR T-cell product satri-cel has been accepted for review by China's NMPA. This marks the world's first CAR T-cell therapy product for solid tumors to reach the NDA stage—a major milestone for the CAR-T field. I extend my sincere gratitude to all clinical investigators, trial coordinators, and patients involved in this program. We are hopeful for its timely approval to provide gastric cancer patients with a new treatment option." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib registrational trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA for the treatment of G/GEJA in September 2020. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgenFor more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store